XTX301, a half-life extended, tumor-selective IL-12, exerts potent anti-tumor activity in mice and has the potential to widen the therapeutic index of IL-12 treatment.

Time: 11:30 am
day: Day Two

Details:

  • mXTX301 potently inhibits tumor growth in a syngeneic mouse model.
  • XTX301 is well-tolerated in a repeat dose non-GLP non-human primate study.
  • XTX301 may exert potent anti-tumor activity while widening the potential therapeutic index of IL-12 treatment.

Speakers: